Coagulation serine proteases

Coagulation serine proteases, most notably Thrombin (Factor IIa) and Factor Xa, are the primary enzymatic drivers of the blood coagulation cascade (UniProt: P00734 [1], P00742 [2]). These enzymes function through a series of proteolytic activations that culminate in the conversion of soluble fibrinogen into an insoluble fibrin clot and the activation of platelets (StatPearls: Physiology, Coagulation Cascade [3]). Pathological overactivity of these proteases leads to thromboembolic diseases such as deep vein thrombosis, pulmonary embolism, and stroke, while deficiencies result in bleeding disorders like hemophilia. As a result, these proteases are critical therapeutic targets for anticoagulant drugs, including direct thrombin inhibitors (e.g., dabigatran) and direct factor Xa inhibitors (e.g., rivaroxaban) (PubChem: Dabigatran [4]). While these therapies are highly effective at preventing thrombosis, they carry a significant risk of major bleeding, which remains the primary safety concern and therapeutic challenge in clinical practice (NIH: Anticoagulants [5]).

Other names

Thrombin and other coagulation proteasesBlood coagulation factorsProcoagulant enzymesFactor IIaFactor XaFactor IXaFactor VIIaFactor XIaFactor XIIa

Direct or indirect inhibition of serine protease activity within the coagulation cascade, thereby preventing the conversion of fibrinogen to fibrin and reducing thrombin-mediated platelet activation (StatPearls: Physiology, Coagulation Cascade [3]).